Jun 2026 (Q2 FY26) — Aug 6, 2026
Xeris Biopharma Q2 FY26 — Record Revenue and Raised Full-Year Guidance
Read the full callXeris Biopharma (XERS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Xeris Biopharma earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 92.1 | +28.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 5.6 | −0.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -31.1 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$10.95 +6.21% · +$0.64
Performance +18.5% 1Y
1Y: $9.24 on 17 Oct 2025 → $10.95. High $10.95 (19 Oct 2026), low $5.29 (24 Mar 2026).
- Previous close
- $10.31
- 52-week range
- $5.29 – $10.95
- One year
- +17.24%
Overview
- Symbol
- XERS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Xeris Biopharma earnings calls (XERS)
Financials
What the filings say
Net profit, year on year: −1513% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 54 | 60 | 60 | 72 | 74 | 86 | 83 | 92 |
| Operating profit | -13 | 2 | -3 | 4 | 7 | 17 | 8 | 5 |
| Operating margin | −23.8% | 2.8% | −5.1% | 6.3% | 9.1% | 19.6% | 9.5% | 5.6% |
| Interest | 8 | 8 | 7 | 7 | 7 | 7 | 7 | 7 |
| Net profit | -16 | -5 | -9 | -2 | 1 | 11 | 2 | -31 |
| EPS ($ per share) | -0.11 | — | -0.06 | -0.01 | 0 | — | 0.01 | -0.18 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -337 | -460 | -555 | -617 | -672 | -671 |
| Total liabilities | 125 | 209 | 299 | 329 | 353 | 370 |
| Fixed assets | 7 | 7 | 6 | 6 | 6 | 5 |
| Investments | 96 | 35 | 0 | 5 | 0 | — |
| Total assets | 159 | 304 | 345 | 323 | 323 | 384 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | -81 | -96 | -103 | -47 | -37 | 29 |
| Cash from investing | -27 | 98 | 34 | -6 | 5 | -1 |
| Cash from financing | 126 | 27 | 127 | -2 | 36 | 11 |
| Net cash flow | — | 30 | 59 | -55 | 4 | 39 |
| Capital expenditure | -0 | -1 | — | — | — | — |
| Free cash flow | -81 | -97 | — | — | — | — |
Insider filings
69 filings between Nov 11, 2025 and Oct 1, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$5.35M
33 sales by 9 insiders
88% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 12
- Award — granted as compensation
- 9
- Option exercise — converted options into shares
- 15
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| McCulloch Kevin | — | $1.48M | Oct 1, 2026 |
| Hecht Beth | — | $1.46M | Oct 1, 2026 |
| JOHNSON JOHN | — | $1.07M | Jun 4, 2026 |
| Pieper Steven | — | $515.2K | Oct 1, 2026 |
| Shannon John Patrick Jr | — | $349.7K | Jan 5, 2026 |
| BORMANN-KENNEDY BARBARA-JEAN ANNE | — | $203.9K | Jun 4, 2026 |
| HALKUFF DAWN | — | $121.9K | Jun 4, 2026 |
| PERSKY MARLA | — | $91.4K | Jun 3, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Hecht Beth See Remarks | Sale 10b5-1 plan | 16,666 | $156.8K |
| Oct 1, 2026 | McCulloch Kevin See Remarks | Sale 10b5-1 plan | 15,000 | $141.1K |
| Oct 1, 2026 | Pieper Steven See Remarks | Sale 10b5-1 plan | 5,000 | $47.0K |
| Sep 28, 2026 | McCulloch Kevin See Remarks | Sale 10b5-1 plan | 25,000 | $250.0K |
| Sep 1, 2026 | Pieper Steven See Remarks | Sale 10b5-1 plan | 5,000 | $42.5K |
| Sep 1, 2026 | McCulloch Kevin See Remarks | Sale 10b5-1 plan | 15,000 | $127.3K |
| Sep 1, 2026 | Hecht Beth See Remarks | Sale 10b5-1 plan | 16,666 | $141.4K |
| Aug 12, 2026 | Pieper Steven See Remarks | Sale 10b5-1 plan | 5,000 | $42.5K |
| Aug 3, 2026 | McCulloch Kevin See Remarks | Sale 10b5-1 plan | 15,000 | $120.2K |
| Aug 3, 2026 | Hecht Beth See Remarks | Sale 10b5-1 plan | 16,666 | $133.6K |
| Aug 1, 2026 | McCulloch Kevin See Remarks | Tax withheld | 21,918 | $177.1K |
| Aug 1, 2026 | Shannon John Patrick Jr See Remarks | Tax withheld | 36,645 | $296.1K |
| Jul 7, 2026 | Pieper Steven See Remarks | Sale 10b5-1 plan | 27,600 | $235.3K |
| Jul 6, 2026 | Pieper Steven See Remarks | Sale 10b5-1 plan | 17,400 | $147.9K |
| Jul 1, 2026 | McCulloch Kevin See Remarks | Sale 10b5-1 plan | 90,000 | $722.5K |
| Jul 1, 2026 | KREHER NERISSA Director | Award | 33,582 | $0 |
| Jul 1, 2026 | Hecht Beth See Remarks | Sale 10b5-1 plan | 16,666 | $133.9K |
| Jun 4, 2026 | HALKUFF DAWN Director | Sale 10b5-1 plan | 20,000 | $121.9K |
| Jun 4, 2026 | BORMANN-KENNEDY BARBARA-JEAN ANNE Director | Award 10b5-1 plan | 24,193 | $0 |
| Jun 4, 2026 | BORMANN-KENNEDY BARBARA-JEAN ANNE Director | Sale 10b5-1 plan | 16,000 | $97.5K |
| Jun 4, 2026 | JOHNSON JOHN Director | Award 10b5-1 plan | 24,193 | $0 |
| Jun 4, 2026 | JOHNSON JOHN Director | Sale 10b5-1 plan | 15,000 | $91.4K |
| Jun 4, 2026 | Brady James Aloysius Director | Award | 24,193 | $0 |
| Jun 4, 2026 | Kong Garheng Director | Award | 24,193 | $0 |
| Jun 4, 2026 | PERSKY MARLA Director | Award 10b5-1 plan | 24,193 | $0 |
| Jun 4, 2026 | HALKUFF DAWN Director | Award 10b5-1 plan | 24,193 | $0 |
| Jun 3, 2026 | PERSKY MARLA Director | Sale 10b5-1 plan | 15,500 | $91.4K |
| Jun 1, 2026 | Hecht Beth See Remarks | Sale 10b5-1 plan | 16,667 | $101.0K |
| May 1, 2026 | Hecht Beth See Remarks | Sale 10b5-1 plan | 16,667 | $103.8K |
| Apr 1, 2026 | Hecht Beth See Remarks | Sale 10b5-1 plan | 16,667 | $99.9K |
| Mar 30, 2026 | Brady James Aloysius Director | Sale 10b5-1 plan | 10,834 | $60.0K |
| Mar 12, 2026 | McCulloch Kevin See Remarks | Option exercise | 48,894 | $200.0K |
| Mar 12, 2026 | McCulloch Kevin See Remarks | Option exercise | 4 | $16 |
| Mar 5, 2026 | Pieper Steven See Remarks | Option exercise | 14,036 | $83.2K |
| Mar 5, 2026 | Pieper Steven See Remarks | Option exercise | 27,891 | $114.1K |
| Mar 2, 2026 | Hecht Beth See Remarks | Sale 10b5-1 plan | 100 | $706 |
| Mar 2, 2026 | Hecht Beth See Remarks | Sale 10b5-1 plan | 16,567 | $103.4K |
| Feb 24, 2026 | Nguyen Anh Tu See Remarks | Tax withheld | 29,300 | $201.6K |
| Feb 2, 2026 | Hecht Beth See Remarks | Sale | 16,667 | $124.1K |
| Jan 31, 2026 | McCulloch Kevin See Remarks | Tax withheld | 27,319 | $201.1K |
| Jan 31, 2026 | McCulloch Kevin See Remarks | Tax withheld | 68,454 | $503.8K |
| Jan 31, 2026 | Pieper Steven See Remarks | Tax withheld | 27,319 | $201.1K |
| Jan 31, 2026 | Pieper Steven See Remarks | Tax withheld | 66,450 | $489.1K |
| Jan 31, 2026 | Pieper Steven See Remarks | Tax withheld | 111,765 | $822.6K |
| Jan 31, 2026 | Hecht Beth See Remarks | Tax withheld | 24,266 | $178.6K |
| Jan 31, 2026 | McCulloch Kevin See Remarks | Tax withheld | 30,289 | $222.9K |
| Jan 31, 2026 | Hecht Beth See Remarks | Tax withheld | 46,914 | $345.3K |
| Jan 31, 2026 | Hecht Beth See Remarks | Tax withheld | 98,375 | $724.0K |
| Jan 31, 2026 | Shannon John Patrick Jr See Remarks | Tax withheld | 111,621 | $821.5K |
| Jan 31, 2026 | Shannon John Patrick Jr See Remarks | Tax withheld | 110,750 | $815.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Xeris Biopharma Holdings, Inc.
Free account. Everything above stays public.
Write why you follow Xeris Biopharma Holdings, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading